Chapter 3 Biology of Cancer
- Overview
- Lung Cancer
- Breast Cancer
- Melanoma
- Colorectal Cancer
- Prostate Cancer
- Cervical Cancer
- Pathogenesis of Cancer
- Genetic Changes
- Stages of Cancer
- The TNM Staging System
- Number Staging Systems
- Cancer Metastases
- Routes of Metastasis
- Drug Resistance
- Inherent Resistance
- Acquired Resistance
Chapter 4 Disease and Economic Burden of Cancer
- Cancer Burden
- Tobacco Use and Statistics
- Alcohol Abuse and Cancer Statistics
- Infectious Diseases and Cancer
- Inherited Genes/Diseases and Cancer
- Sun, Ultraviolet Radiation and Cancer
- Hormones and Cancer
- Cancer: A Statistical Analysis of the Disease Incidence and Prevalence
- Incidence and Prevalence Rates for Major Cancer Types
- Regional Patterns of Cancer
- Europe
- North America
- Asia-Pacific
- Latin and Central America
- Middle East and Africa
Chapter 5 Treatment Approaches to Cancer Metastases and Recurrence
- Treatment Approaches to Cancer Metastases and Recurrence
- Non-pharmaceutical Approaches
- Surgery for Cancer
- Radiotherapy for Cancer
- Ablation Therapy
- Pharmacological Therapies
- Cytotoxic Cancer Chemotherapy
- Hormone-based Cancer Drugs
- Targeted Biologic Therapy
- Monoclonal Antibodies
- Immune Checkpoint Inhibitors
- Cancer Growth Blockers
- Gene Therapy
- Drugs That Block Cancer Blood Vessel Growth (Antiangiogenics)
- Personalized Cancer Therapy (Precision Medicine)
- Treatment Options for Selected Cancer Metastases
- Breast
- Bladder Cancer
- Lung
- Colorectal Cancer
- Standard Treatment Options for Stage IV and Recurrent Colon Cancer
- Prostate Cancer
- Stomach Cancer
- Melanoma
- Kidney Cancer
- Transitional Cell Cancer (TCC) of the Renal Pelvis and Ureter
- Pancreatic Cancer
- Thyroid Cancer
- Stage I and Stage II Endometrial Cancer
- Stage III, Stage IV and Recurrent Endometrial Cancer
Chapter 6 Cancer Therapeutics: Marketed Products and Pipeline Analysis
- Overview
- Top Selling Oncology Drugs in 2017
- Profiles of Selected Marketed Drugs
- Clinical Trials
- Lung Cancer
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trial
- Breast Cancer
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trials
- Colorectal Cancer
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trials
- Bladder Cancer
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trials
- Gastric Cancer
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trials
- Others (Kidney Cancer, Lymphoma, Leukemia, Ovarian, Pancreatic)
- Phase III Clinical Trials
- Phase II Clinical Trials
- Phase I Clinical Trials
Chapter 7 Regulations and Reimbursement Landscape
- The United States
- Canada
- Europe
- Mutual Recognition Procedure (MRP)
- Decentralized Procedure (DCP)
- Centralized Procedure (CP)
- Japan
- Marketing Authorization System
- Pharmaceutical Reimbursement Approval Process in Japan
- China
- Pharmaceutical Regulatory and Legislative Developments in China
- India
- Pharmaceutical Regulatory and Legislative Developments in India
- South Korea
- Regulatory and Legislative Requirements
- Pharmaceutical Regulatory and Legislative Developments in South Korea
- Pharmaceutical Reimbursement Landscape in South Korea
- Brazil
- Market Entry and Reimbursement of Pharmaceuticals
- Argentina
- Regulatory and Legislative Requirements
- Mexico
- Regulation and Regulation Governing Drugs in Mexico
- Health Insurance Structure in Mexico
- South Africa
- Regulatory Requirementsin South Africa
- Health Insurance Structure in South Africa
- Reimbursement of Pharmaceuticals in South Africa
- Saudi Arabia
- Pharmaceutical Regulatory Requirements in Saudi Arabia
- Health Insurance Structure in Saudi Arabia
Chapter 8 Cancer Therapeutics: Analysis of Global and Regional Markets
- Overview
- Global Cancer Therapeutics Market
- Market Drivers
- Market Restraints
- Market Opportunities
- North America
- Market Dynamics in North America
- United States
- Canada
- Europe
- Market Drivers
- Market Restraints
- France
- Germany
- U.K.
- Spain
- Italy
- Asia-Pacific
- Market Drivers
- Market Restraints
- Japan
- China
- India
- Central and Latin America
- Market Drivers
- Market Restraints
- Brazil
- Argentina
- Middle East and Africa
- Market Drivers
- Market Restraints
Chapter 9 Patent Review/New Developments
- Patent Applications by Clinical Application
- Patent Applications Filed on Metastatic Breast Cancer Therapeutics
- Patent Applications Filed on Metastatic Prostate Cancer Therapeutics
- Patent Applications Filed on Metastatic Lung Cancer Therapeutics
- Patents Applications Filed on Therapeutics for Other Cancer Types
- Patents and Expiry Dates for Major Products by Leading Suppliers
- Pfizer Inc.
- Merck & Co.
- Johnson & Johnson
- F Hoffman-La Roche
- Sanofi SA
- Novartis AG
- AbbVie, Inc.
- AstraZeneca plc
- Celgene
- Eli Lilly
- Gilead Sciences
- Patents and Expiry Dates for Other Products and Suppliers
- Targeting Breakpoint Cluster Region-Abelson (BCR-ABL)
- Targeting Epidermal Growth Factor Receptor (EGFR/ERBB1)
- Targeting Vascular Endothelial Growth Factor Receptor (VEGFR), PDGFR and Ret Proto-Oncogene (RET)
- Impact of Patent Expiries
Chapter 10 Competitive Landscape
- Overview
- Leading Companies
- Roche
- Novartis
- Celgene
- Bristol-Meyers Squibb
- Johnson & Johnson
- Recent Developments
Chapter 11 Company Profiles
- ABBVIE, INC.
- Company Overview
- Financial Information
- Products
- Clinical Developments
- AMGEN
- Company Overview
- Financial Information
- Products
- ARRAY BIOPHARMA INC.
- Company Overview
- Products
- AstraZeneca plc
- Company Overview
- Financial Information
- Key Developments
- ASTELLAS PHARMA INC.
- Company Overview
- Products
- BAYER HEALTHCARE
- Company Overview
- Products
- BRISTOL-MYERS SQUIBB
- Company Overview
- Financial Information
- Products
- BIOGEN INC.
- Company Overview
- CELGENE CORP.
- Company Overview
- Financial Information
- Products
- CELLDEX THERAPEUTICS INC.
- Company Overview
- Products
- GLAXOSMITHKLINE
- Company Overview
- GILEAD SCIENCES, INC.
- Company Overview
- Product
- ELI LILLY AND CO.
- Company Overview
- Financial Information
- Products
- EISAI CO. LTD.
- Company Overview
- Products
- F HOFFMAN-LA ROCHE LTD.
- Company Overview
- Financial Information
- Products
- Key Developments
- IMMUNOCELLULAR THERAPEUTICS LTD.
- Company Overview
- Products
- IMMUNOGEN INC.
- Company Overview
- INCYTE CORP.
- Company Overview
- INFINITY PHARMACEUTICALS, INC.
- Company Overview
- JOHNSON & JOHNSON
- Company Overview
- Financial Information
- Products
- MERCK & CO., INC.
- Financial Information
- Products
- NOVARTIS AG
- Company Overview
- Financial Information
- Products
- Clinical Development
- Key Developments
- NEW LINK GENETICS CORP.
- Company Overview
- OTSUKA HOLDINGS CO. LTD.
- Company Overview
- PFIZER INC.
- Company Overview
- Financial Information
- Key Developments
- REGENERON PHARMACEUTICALS INC.
- Company Overview
- SANOFI SA
- Company Overview
- Financial Information
- Products
- Key Developments
- SELLAS LIFE SCIENCES GROUP
- Company Overview
- TAKEDA PHARMACEUTICALS
- Company Overview
- VERASTEM INC.
- Company Overview
List of Tables
Summary Table: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 1: Cancer Incidence in the U.S., by Sex, 2017
Table 2: Number of Deaths from Cancer in the U.S., by Sex, 2017
Table 3: Cancer Treatment Options
Table 4: Cancer Drug Treatment Classes
Table 5: FDA-Approved Intravenous Therapeutic Monoclonal Antibodies Used to Treat Cancer, 1997-2017
Table 6: Approved Tyrosine Kinase Inhibitors (TKIs) Used to Treat Cancer
Table 7: Common Chemotherapeutic Agents for Recurrent and Metastatic Breast Cancer
Table 8: Drugs Approved for the Treatment of Lung Cancer
Table 9: Treatment Options for Stage IV and Recurrent Colon Cancer
Table 10: Hormone Therapy for Prostate Cancer
Table 11: Drugs Approved for Prostate Cancer
Table 12: Drugs Approved for Stomach (Gastric) Cancer
Table 13: Drugs Combinations Approved for Stomach (Gastric) Cancer
Table 14: Drugs Approved for Gastroenteropancreatic Neuroendocrine Tumors
Table 15: Drugs Approved for the Treatment of Melanoma
Table 16: Drugs Approved for Pancreatic Cancer
Table 17: Drugs Approved for Pancreatic Cancer
Table 18: Treatment Option Overview for Thyroid Cancer
Table 19: Drugs Approved for Thyroid Cancer
Table 20: Treatment Option Overview for Endometrial Cancer
Table 21: Profiles of Top Marketed Drugs
Table 22: Lung Cancer Phase III Clinical Trials, 2018*
Table 23: Lung Cancer Phase II Clinical Trials, 2018*
Table 24: Lung Cancer Phase I Clinical Trials, 2018*
Table 25: Breast Cancer Phase III Clinical Trials, 2018*
Table 26: Breast Cancer Phase II Clinical Trials, 2018*
Table 27: Breast Cancer Phase I Clinical Trials, 2018*
Table 28: Colorectal Cancer Phase III Clinical Trials, 2018*
Table 29: Colorectal Cancer Phase II Clinical Trials, 2018*
Table 30: Colorectal Cancer Phase I Clinical Trials, 2018*
Table 31: Bladder Cancer Phase III Clinical Trials, 2018*
Table 32: Bladder Cancer Phase II Clinical Trials, 2018*
Table 33: Bladder Cancer Phase I Clinical Trials, 2018*
Table 34: Gastric Cancer Phase III Clinical Trials, 2018*
Table 35: Gastric Cancer Phase II Clinical Trials, 2018*
Table 36: Gastric Cancer Phase I Clinical Trials, 2018*
Table 37: Others Phase III Clinical Trials, 2018*
Table 38: Others Phase II Clinical Trials, 2018*
Table 39: Others Phase I Clinical Trials, 2018*
Table 40: Global Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 41: North American Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 42: North American Cancer Therapeutics Market, by Country, Through 2023
Table 43: European Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 44: European Cancer Therapeutics Market, by Country, Through 2023
Table 45: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 46: Asia-Pacific Cancer Therapeutics Market, by Country, Through 2023
Table 47: Central and Latin American Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 48: Central and Latin American Cancer Therapeutics Market, by Country, Through 2023
Table 49: Middle East and Africa Cancer Therapeutics Market, by Cancer Type, Through 2023
Table 50: Patent Applications Filed on Metastatic Breast Cancer Therapeutics, 2016 - October 2017
Table 51: Patent Applications Filed on Metastatic Prostate Cancer Therapeutics, November 2015 - January 2018
Table 52: Patent Applications Filed on Metastatic Lung Cancer Therapeutics, August 2015 - January 2018
Table 53: Latest Patent Publications Cited Relating to Other Metastatic Cancers, December 2015 - July 2018
Table 54: Pfizer Inc.: Patent Expiry Dates for Leading Cancer Drugs
Table 55: Merck & Co.: Patent Status of Leading Oncology Products
Table 56: Johnson & Johnson: Patent Status of Leading Oncology Products
Table 57: F Hoffman-La Roche: Patent Status of Leading Oncology Products
Table 58: Sanofi SA: Patent Status of Leading Oncology Products
Table 59: AstraZeneca plc: Patent Status of Leading Oncology Products
Table 60: Celgene: Patent Status of Leading Oncology Products
Table 61: Eli Lilly: Patent Status of Leading Oncology Products
Table 62: Recent Industry Developments, December 2017 Through September 2018
Table 63: AbbVie, Inc.: Company Financials, by Product, 2015-2017
Table 64: Amgen: Company Financials, 2015-2017
Table 65: Array Biopharma Inc.: Clinical Stage Drug Portfolio
Table 66: AstraZeneca plc.: Company Net Revenue, 2015-2017
Table 67: AstraZeneca plc: Company Financials, by Therapeutic Product Group, 2015-2017
Table 68: AstraZeneca plc: Company Financials, by Oncology Product Group, 2015-2017
Table 69: Bristol-Myers Squibb: Revenue, 2015-2017
Table 70: Bristol-Myers Squibb: Oncology Product Sales, 2015-2017
Table 71: Celgene Corp.: Company Financials, by Product, 2015-2017
Table 72: GlaxoSmithKline: Oncology Product Pipeline
Table 73: Gilead Sciences, Inc.: Product Pipeline
Table 74: Eli Lilly and Co.: Net Revenue, by Segment, 2015-2017
Table 75: Eli Lilly and Co.: Oncology Product Sales, 2015-2017
Table 76: F Hoffmann-La Roche Ltd.: Net Revenue, by Segment, 2015-2017
Table 77: F Hoffman-La Roche Ltd.: Pharmaceutical Division Oncology Product Sales, 2015-2017
Table 78: Johnson & Johnson: Company Financials, by Segment, 2015-2017
Table 79: Johnson & Johnson: Pharmaceutical Therapeutic Area Product Sales, 2015-2017
Table 80: Johnson & Johnson: Oncology Product Sales, 2015-2017
Table 81: Merck & Co., Inc.: Therapeutic Area Product Sales, 2015-2017
Table 82: Merck & Co., Inc.: Oncology Product Sales, 2015-2017
Table 83: Novartis AG: Company Financials, by Business Segment, 2015-2017
Table 84: Novartis AG: Major Development Projects
Table 85: Pfizer Inc.: Company Financials, 2015-2017
Table 86: Pfizer Inc.: Innovative Health (IH) Division Financials, 2015-2017
Table 87: Pfizer Inc.: Innovative Health (IH) Division Oncology Product Sales, 2015-2017
Table 88: Sanofi SA: Company Financials, 2015-2017
Table 89: Sanofi SA: Oncology Product Sales, 2015-2017
Table 90: Commonly Used Acronyms Associated with Metastatic and Recurrent Cancer
List of Figures
Summary Figure: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
Figure 1: Top Selling Oncology Drugs, 2017
Figure 2: Distribution of Clinical Trials for Cancer Metastases and Recurrence, by Cancer Type, 2018*
Figure 3: Global Cancer Therapeutics Market, 2017-2023
Figure 4: Global Cancer Therapeutics Market Share, by Cancer Type, 2017
Figure 5: North American Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 6: European Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 7: Asia-Pacific Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 8: Central and Latin American Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 9: Middle East and African Cancer Therapeutics Market, by Cancer Type, 2017-2023
Figure 10: Global Cancer Therapeutics Market Share, by Company, 2017
